Provided by Tiger Trade Technology Pte. Ltd.

GRAIL, Inc.

143.26
+10.708.07%
Post-market: 143.430.1742+0.12%19:59 EDT
Volume:875.34K
Turnover:123.26M
Market Cap:6.40B
PE:-14.70
High:143.50
Open:135.52
Low:134.45
Close:132.56
52wk High:151.46
52wk Low:41.50
Shares:44.67M
Float Shares:40.70M
Volume Ratio:0.69
T/O Rate:2.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.7487
EPS(LYR):-11.1105
ROE:-16.12%
ROA:-12.03%
PB:2.52
PE(LYR):-12.89

Loading ...

Piper Sandler Remains a Hold on GRAIL Inc (GRAL)

TIPRANKS
·
Jun 02

Grail assumed with a Peer Perform at Wolfe Research

TIPRANKS
·
Jun 02

Sector Update: Healthcare Stocks Fall in Afternoon Trading

MT Newswires Live
·
Jun 02

BUZZ-U.S. STOCKS ON THE MOVE-Grail, Kohl, Virgin Galactic

Reuters
·
Jun 02

Grail falls -18.4%

TIPRANKS
·
Jun 02

BUZZ-Grail shares fall after large cancer blood test data yields mixed results

Reuters
·
Jun 02

Grail posts ASCO presentation on private-practice adoption of multi-cancer early detection test

Reuters
·
Jun 01

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as AI Optimism Overshadows Middle East Risks

MT Newswires Live
·
Jun 01

GRAIL Shares Fall Pre-Bell After Galleri Trial Misses Primary Endpoint

MT Newswires Live
·
Jun 01

Canaccord Genuity Keeps Their Buy Rating on GRAIL Inc (GRAL)

TIPRANKS
·
Jun 01

Grail's Galleri Test Improves Cancer Detection in Pathfinder 2 Trial

MT Newswires Live
·
Jun 01

Grail presents ‘positive’ performance, safety results from Pathfinder 2 study

TIPRANKS
·
Jun 01

Grail reports results from NHS-Galleri trial in presentation at ASCO meeting

TIPRANKS
·
Jun 01

Grail Presents Pathfinder 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 Asco Annual Meeting

THOMSON REUTERS
·
May 31

BRIEF-Grail Reports Full Results From Nhs-Galleri Trial Demonstrating Substantial Reduction In Stage Iv Cancer Diagnoses

Reuters
·
May 30

Grail - Galleri Blood Test Reduces Stage Iv Diagnoses by 22% in Second and 26% in Third Rounds

THOMSON REUTERS
·
May 30

Grail Reports Full Results From Nhs-Galleri Trial Demonstrating Substantial Reduction in Stage Iv Cancer Diagnoses at 2026 Asco Annual Meeting

THOMSON REUTERS
·
May 30

Grail Inc - No Reduction Observed in Combined Primary Endpoint of Stage Iii/Iv Cancers in Aggregate

THOMSON REUTERS
·
May 30

Grail grants 34,350 RSUs to 56 new hires under inducement equity plan

Reuters
·
May 28

Grail Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 28